about
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cellsHIV infection, aging, and immune function: implications for cancer risk and preventionInhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells.The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents.The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future researchChanging patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDSUse of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.Paclitaxel for AIDS-associated Kaposi's sarcoma.Kaposi's sarcoma and its associated herpesvirus.The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro.Liposomal daunorubicin as treatment for Kaposi's sarcomaTargeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential.Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer.Repositioning HIV protease inhibitors as cancer therapeuticsThe HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines.Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana.Pharmacological management of Kaposi's sarcoma.Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment.Targeting endoplasmic reticulum signaling pathways in cancer.The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivoKSHV Down-regulates Tropoelastin in Both an in-vitro and in-vivo Kaposi's Sarcoma Model.Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.High-mobility group box 1 protein is involved in the protective effect of Saquinavir on ventilation-induced lung injury in mice.Therapeutics in renal disease: the road ahead for antiproliferative targets.The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.The oncology impact of highly active antiretroviral therapyInhibitors of HIV-1 protease: 10 years afterSaquinavir-NO Inhibits IL-6 Production in Macrophages
P2860
Q24628715-FA73D166-29E8-4D1A-8F76-DFFBD5145950Q27004165-0FAC1139-BA84-48A1-9062-B85F3400CE89Q33684710-D39D1457-CF6C-4670-AFBB-F66F8592102DQ33714126-E26EC506-0B62-4A29-918A-D2E583B960CDQ33803248-16299BB6-2DC8-4555-B3C7-DE2437655B7BQ33898366-C6A22A88-AA74-4794-83F1-B391D0C24C54Q34059657-0018C2CD-04DA-471A-8366-B1AD7CAFBEECQ34663095-BF6DDB18-263B-445E-8930-D2EA0E006DEEQ35715660-65454DCD-2A2A-4272-82CC-1119E0FBF95AQ35895560-162F9722-71E0-4723-98EC-D664C5ECD030Q36118375-18209DD5-799E-4C1A-BCFB-77E92A0227E4Q36487309-4F5958D5-EF1B-47AE-9825-7B602A499A83Q36563576-1C65E720-A4BE-4852-9BBD-2E2892C4E45CQ36736534-B055EC2E-B0CF-4626-85EB-C33F76C50584Q36930009-99B2C944-5B74-4DF1-AAAA-769E33BD7C84Q37004096-3BC82A2C-7748-408C-BB91-3F112FB50F4AQ37061986-2F7BD3E8-A220-4424-A6D0-B9714D17FFE2Q37129860-A4DE4B9F-F206-4DE2-974B-60C0E5A0B24BQ37192579-A1630EF7-862D-4104-BAEA-E2DE220E6195Q37288354-17D0E24B-9D67-4D8A-870A-E6524128C0D5Q37868477-8758E60B-3CDD-4C30-8A3D-EB5E3FD56EC0Q37868566-8430B2C0-E3E5-4F79-AC62-4E5868064395Q37888397-720B74F3-C3ED-46BF-BEE9-3FABC7356FDFQ38017716-DF73255B-B81B-4259-81BB-D446272F3B24Q39407246-667FCE7C-5DAA-4819-8425-D793885EBF33Q40718646-4CA0B31C-AE38-4E49-871A-B19B7871FCF0Q41140055-1D121A3E-077B-48BC-A4B3-E713B061321CQ42225690-E37CCE89-F345-415E-8DD7-8BD8C4A4FB17Q42473677-6F634625-D9DB-41BD-BEAD-0AC312F6CAF3Q47692695-ED7939FA-E78F-43EC-9A88-9C20EBFA12B5Q53644742-DA715F39-6A06-4AD1-A759-872195466FACQ54215275-E51CBDA0-08CD-4241-BA32-7AFE9B26EAACQ57832203-20F84AD9-4EA2-43C4-AC67-B1CCEBF4507EQ58389026-3AFD9AE0-579F-4976-933E-786FB1AEA5C3Q59089968-8F83AA80-AC80-45CB-972D-EF82D6A05472
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antitumour effects of antiretroviral therapy.
@ast
Antitumour effects of antiretroviral therapy.
@en
type
label
Antitumour effects of antiretroviral therapy.
@ast
Antitumour effects of antiretroviral therapy.
@en
prefLabel
Antitumour effects of antiretroviral therapy.
@ast
Antitumour effects of antiretroviral therapy.
@en
P2860
P50
P356
P1476
Antitumour effects of antiretroviral therapy.
@en
P2093
Elena Toschi
Giovanni Barillari
P2860
P2888
P304
P356
10.1038/NRC1479
P407
P577
2004-11-01T00:00:00Z